225 related articles for article (PubMed ID: 27478390)
1. Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
Crandell JR
Clin Med Insights Cardiol; 2016; 10():123-8. PubMed ID: 27478390
[TBL] [Abstract][Full Text] [Related]
2. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
3. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl.
Hassan A; Tajuddin N; Shaikh A
Cardiol Ther; 2015 Jun; 4(1):83-93. PubMed ID: 25515964
[TBL] [Abstract][Full Text] [Related]
5. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
6. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Kim ES; McCormack PL
Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
[TBL] [Abstract][Full Text] [Related]
7. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
[No Abstract] [Full Text] [Related]
8. Overview of omega-3 Fatty Acid therapies.
Bradberry JC; Hilleman DE
P T; 2013 Nov; 38(11):681-91. PubMed ID: 24391388
[TBL] [Abstract][Full Text] [Related]
9. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
10. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
11. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
[TBL] [Abstract][Full Text] [Related]
12. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.
Ballantyne CM; Manku MS; Bays HE; Philip S; Granowitz C; Doyle RT; Juliano RA
Cardiol Ther; 2019 Jun; 8(1):79-90. PubMed ID: 30788718
[TBL] [Abstract][Full Text] [Related]
13. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
Brinton EA; Mason RP
Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
[TBL] [Abstract][Full Text] [Related]
14. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
15. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.
Tajuddin N; Shaikh A; Hassan A
Diabetes Metab Syndr Obes; 2016; 9():109-18. PubMed ID: 27143943
[TBL] [Abstract][Full Text] [Related]
16. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
[TBL] [Abstract][Full Text] [Related]
17. Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.
Castaldo RS
Drugs Ther Perspect; 2016; 32():162-169. PubMed ID: 27065746
[TBL] [Abstract][Full Text] [Related]
18. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
Reddy KJ; Chowdhury S
Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
20. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
Ballantyne CM; Braeckman RA; Bays HE; Kastelein JJ; Otvos JD; Stirtan WG; Doyle RT; Soni PN; Juliano RA
J Clin Lipidol; 2015; 9(3):377-83. PubMed ID: 26073397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
